How CRISPR is tackling the troubling immune response that’s plagued gene therapy until now

One of the major challenges facing gene therapy — a way to treat disease by replacing a patient’s defective genes with healthy ones — is that it is difficult to safely deliver therapeutic genes to patients without the immune system destroying the gene, and the vehicle carrying it, which can trigger life-threatening widespread inflammation. Three decades ago researchers thought that gene therapy would be the ultimate treatment for genetically inherited diseases like hemophilia, sickle cell anemia, and genetic diseases of metabolism. But the technology couldn’t dodge the immune response. Since then, researchers have been looking for ways to perfect the…

This story continues at The Next Web

from The Next Web https://ift.tt/2FqoaSZ